KEGG   DRUG: Romosozumab
Entry
D10156                      Drug                                   

Name
Romosozumab (USAN);
Romosozumab (genetical recombination) (JAN);
Romosozumab-aqqg;
Evenity (TN)
Product
Formula
C6452H9926N1714O2040S54
Exact mass
145785.0578
Mol weight
145875.6186
Remark
Therapeutic category: 3999
ATC code: M05BX06
Product: D10156<JP/US>
Efficacy
Osteoporosis agent, Sclerostin activity inhibitor
  Disease
Osteoporosis [DS:H01593]
Comment
Monoclonal antibody
Treatment of osteoporosis
Target
SOST [HSA:50964] [KO:K16834]
  Pathway
hsa04310  Wnt signaling pathway
Brite
Anatomical Therapeutic Chemical (ATC) classification [BR:br08303]
 M MUSCULO-SKELETAL SYSTEM
  M05 DRUGS FOR TREATMENT OF BONE DISEASES
   M05B DRUGS AFFECTING BONE STRUCTURE AND MINERALIZATION
    M05BX Other drugs affecting bone structure and mineralization
     M05BX06 Romosozumab
      D10156  Romosozumab (USAN) <JP/US>
USP drug classification [BR:br08302]
 Metabolic Bone Disease Agents
  Vitamin D-related Agents
   Romosozumab
    D10156  Romosozumab (USAN)
Therapeutic category of drugs in Japan [BR:br08301]
 3  Agents affecting metabolism
  39  Other agents affecting metabolism
   399  Miscellaneous
    3999  Others
     D10156  Romosozumab (USAN); Romosozumab (genetical recombination) (JAN)
Target-based classification of drugs [BR:br08310]
 Not elsewhere classified
  Signaling molecules
   Wnt signaling
    SOST
     D10156  Romosozumab (USAN) <JP/US>
New drug approvals in the USA [br08319.html]
 New molecular entities and new therapeutic biological products
  D10156
New drug approvals in Europe [br08329.html]
 European public assessment reports (EPAR) authorised medicine
  D10156
New drug approvals in Japan [br08318.html]
 Drugs with new active ingredients
  D10156
New drug approvals in the USA, Europe and Japan [br08328.html]
 Approval dates by FDA, EMA and PMDA
  D10156
Other DBs
CAS: 909395-70-6
PubChem: 135626874
LinkDB

» Japanese version   » Back

DBGET integrated database retrieval system